The relationship between myocardial fibrosis and myocardial microRNAs in dilated cardiomyopathy: A link between mir-133a and cardiovascular events

Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy

(2017) Paweł Rubiś et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study

(2017) Nick van Boven et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy

(2016) Christian Besler et al.   EUROPEAN JOURNAL OF HEART FAILURE

MicroRNAs in heart failure: from biomarker to target for therapy

(2016) Eline L. Vegter et al.   EUROPEAN JOURNAL OF HEART FAILURE

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2015) Roberto M. Lang et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes

(2014) Shali Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

MicroRNAs in Vascular and Metabolic Disease

(2012) Anna Zampetaki et al.   CIRCULATION RESEARCH

MicroRNA-24 regulates cardiac fibrosis after myocardial infarction

(2012) Jue Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

MicroRNAs as a therapeutic target for cardiovascular diseases

(2009) Paras Kumar Mishra et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

miR-133 and miR-30 Regulate Connective Tissue Growth Factor

(2008) Rudy F. Duisters et al.   CIRCULATION RESEARCH